April 24, 2020 4:00 PM ET
NATICK, Massachusetts, April 24, 2020 — HebeCell Corp (“HebeCell”) today announced that it has closed a US$10 million Pre-Series A financing to further advance the research and development of its leading patented scalable natural killer (NK) cell platform technology. Aceso Biotech Venture Fund invested in this round of financing.
The new investment will enable HebeCell to establish its position as a leader in large scale production of NK cells from regular or engineered human pluripotent stem cells (hPSC) in the US and internationally. The construction and development of a new GMP facility is also a key area of focus for HebeCell’s next phase development, which will get generous support. The funding will also drive further collaborations with current and potential partners as well.
“We believe our novel scalable platform represents the next generation technology of hPSC-derived NK cell therapies that is more effective, safer and cost effective. hPSC-derived NK-based therapies will be applied not only to immune-oncology, but to many other diseases such as viral infectious diseases such as COVID-19 and autoimmune diseases” – Allen Feng, CSO
About HebeCell Corp
HebeCell Corp, a Delaware corporation based in Natick Massachusetts was founded in 2016 by a group of scientists who wanted to push research in regenerative medicine and immuno-oncology farther than ever before. HebeCell’s team of researchers includes multiple world-leading experts in stem cell biology, as well as experienced entrepreneurs and business developers. The company operates a fully equipped state-of-the-art laboratory in Natick, MA, one of the world’s largest biotech hubs.
About Aceso Biotech Venture Fund
Aceso Biotech Venture Fund, LP., a Delaware Limited Partnership, is a venture capital investment fund focusing on biotech technology and is managed by its general partner Aceso Biotech Capital Partners, LLC, a Delaware limited liability company based in Boston, MA and Kansas City, KS. Its management team has many years’ experience of investment in biotech and biopharma areas domestically and globally.
Media Contact:
Jake Hao
(508) 545-2190
jhao@hebecell.com
www.Hebecell.com
SOURCE: HebeCell Corp.